Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Coyne

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
NEJM Evidence|August 26, 2024
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney DiseaseJeffrey T Ha, Swapnil Hiremath, Min Jun, et al.
Metabolism: Clinical and Experimental|February 8, 2002
Variation in plasma leptin concentrations after unilateral nephrectomyMary Ellen Beindorff, Kevin M Larkin, Daniel W Coyne, et al.
American Journal of Nephrology|November 16, 2007
C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeksBruce Spinowitz, Daniel W Coyne, Charmaine E Lok, et al.
American Journal of Nephrology|March 8, 2018
Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric OxyhydroxideKamyar Kalantar-Zadeh, Vidhya Parameswaran, Linda H Ficociello, et al.
Journal of the American Society of Nephrology : JASN|January 25, 2008
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritinToros Kapoian, Neeta B O'Mara, Ajay K Singh, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2015
A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patientsSunil Bhandari, Philip A Kalra, Jatin Kothari, et al.
Drugs in R&D|September 15, 2017
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D<sub>3</sub>) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on HemodialysisRicha Pandey, Julia B Zella, Jinge G Zhu, et al.
Kidney International Reports|January 1, 2020
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular CalcificationDaniel W Coyne, Hem N Singh, William T Smith, et al.
Clinical Nephrology|June 8, 2017
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
Daniel W Coyne, Linda H Ficociello, Vidhya Parameswaran, et al.
American Journal of Nephrology|June 13, 2009
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristicsH J Lambers Heerspink, R Agarwal, D W Coyne, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
NEJM Evidence|August 26, 2024
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney DiseaseJeffrey T Ha, Swapnil Hiremath, Min Jun, et al.
Metabolism: Clinical and Experimental|February 8, 2002
Variation in plasma leptin concentrations after unilateral nephrectomyMary Ellen Beindorff, Kevin M Larkin, Daniel W Coyne, et al.
American Journal of Nephrology|November 16, 2007
C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeksBruce Spinowitz, Daniel W Coyne, Charmaine E Lok, et al.
American Journal of Nephrology|March 8, 2018
Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric OxyhydroxideKamyar Kalantar-Zadeh, Vidhya Parameswaran, Linda H Ficociello, et al.
Journal of the American Society of Nephrology : JASN|January 25, 2008
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritinToros Kapoian, Neeta B O'Mara, Ajay K Singh, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2015
A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patientsSunil Bhandari, Philip A Kalra, Jatin Kothari, et al.
Drugs in R&D|September 15, 2017
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D<sub>3</sub>) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on HemodialysisRicha Pandey, Julia B Zella, Jinge G Zhu, et al.
Kidney International Reports|January 1, 2020
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular CalcificationDaniel W Coyne, Hem N Singh, William T Smith, et al.
Clinical Nephrology|June 8, 2017
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
Daniel W Coyne, Linda H Ficociello, Vidhya Parameswaran, et al.
American Journal of Nephrology|June 13, 2009
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristicsH J Lambers Heerspink, R Agarwal, D W Coyne, et al.
Pageof 10